tradingkey.logo
tradingkey.logo
Search

Celldex Therapeutics Inc

CLDX
Add to Watchlist
36.780USD
-0.430-1.16%
Close 07/01, 16:00ETQuotes delayed by 15 min
2.44BMarket Cap
LossP/E TTM

TradingKey Stock Score of Celldex Therapeutics Inc

Currency: USD Updated: 2026-06-30

Key Insights

Celldex Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 63 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 57.53.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Celldex Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
63 / 387
Overall Ranking
149 / 4569
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Celldex Therapeutics Inc Highlights

StrengthsRisks
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.54M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.54M.
Fairly Valued
The company’s latest PE is -8.72, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.58M shares, decreasing 7.88% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 3.24M shares of this stock.

Analyst Rating

Based on 16 analysts
Buy
Current Rating
57.533
Target Price
+54.62%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Celldex Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Celldex Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Celldex Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of Celldex Therapeutics Inc?

To generate the financial health score of Celldex Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Celldex Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Celldex Therapeutics Inc.

How do we generate the company valuation score of Celldex Therapeutics Inc?

To generate the company valuation score of Celldex Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Celldex Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Celldex Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Celldex Therapeutics Inc.

How do we generate the earnings forecast score of Celldex Therapeutics Inc?

To calculate the earnings forecast score of Celldex Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Celldex Therapeutics Inc’s future.

How do we generate the price momentum score of Celldex Therapeutics Inc?

When generating the price momentum score for Celldex Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Celldex Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Celldex Therapeutics Inc.

How do we generate the institutional confidence score of Celldex Therapeutics Inc?

To generate the institutional confidence score of Celldex Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Celldex Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Celldex Therapeutics Inc.

How do we generate the risk management score of Celldex Therapeutics Inc?

To assess the risk management score of Celldex Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Celldex Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Celldex Therapeutics Inc.